Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to 13.2%.

  • Amphastar Pharmaceuticals' EBITDA Margin fell 166400.0% to 13.2% in Q3 2025 from the same period last year, while for Sep 2025 it was 20.73%, marking a year-over-year decrease of 88800.0%. This contributed to the annual value of 28.06% for FY2024, which is 25100.0% down from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its EBITDA Margin stood at 13.2% for Q3 2025, which was down 166400.0% from 24.19% recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' EBITDA Margin ranged from a high of 40.25% in Q3 2023 and a low of 10.0% during Q1 2021
  • Moreover, its 5-year median value for EBITDA Margin was 23.88% (2023), whereas its average is 23.12%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first surged by 209200bps in 2023, then crashed by -166400bps in 2025.
  • Amphastar Pharmaceuticals' EBITDA Margin (Quarter) stood at 20.06% in 2021, then soared by 40bps to 28.02% in 2022, then increased by 8bps to 30.31% in 2023, then decreased by -20bps to 24.2% in 2024, then plummeted by -45bps to 13.2% in 2025.
  • Its EBITDA Margin was 13.2% in Q3 2025, compared to 24.19% in Q2 2025 and 21.87% in Q1 2025.